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Abstract 
 
Purpose 
 
To compare the refractive outcome of eyes that underwent phacoemulsification combined with endoscopic 
cyclophotocoagulation (phaco-ECP) with the eyes that underwent phacoemulsification alone. 
 
Methods 
 
A retrospective case series review of 103 consecutive eyes that underwent phaco-ECP and 62 eyes that 
underwent phacoemulsification between January 2006 and August 2012 was conducted. Post-operative 
refractive outcomes were obtained by subjective refraction or autorefraction. Demographic data, best corrected 
visual acuity (BCVA), intraocular pressure (IOP), number of glaucoma agents and mean deviation of the 
Humphrey visual field test (MD) were also analysed.   
 
Results 
 
The total number of eyes included in the study was 62 eyes for the phaco-ECP group and 62 eyes for the control 
group who underwent phacoemulsification alone. More than 90% of eyes (n=56) in phaco-ECP group achieved 
post-operative refraction within +/- 1 dioptre (D) of the target refraction. In the control group 100% of eyes 
achieved post-operative refraction within +/- 1D of the target refraction. When comparing the difference 
between the target and the actual refractive outcome between the phaco-ECP and the control group, there was 
no statistically significant difference.  
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Conclusions 
 
Refractive outcome after phaco-ECP is comparable to phacoemulsification alone. This study suggests that the 
intraocular lens power can be selected as for cataract surgery alone and that ECP does not change the effective 
lens position significantly, therefore no modification of biometry formulae is required. Phaco-ECP should be 
considered as an effective, safe and predictable surgical treatment option for glaucoma patients with co-existing 
cataract.  
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Introduction 
 
Patients with glaucoma frequently develop cataract due to a number of plausible reasons such as the use of 
topical medications and previous laser or surgical procedures as well as physiological aging.1 Cataract itself may 
create challenges in glaucoma management by reducing vision, obstructing aqueous outflow and by making 
perimetry and optic disc assessment more difficult.  Therefore, the timely management of both conditions is co-
dependent in improving outcome.   
 
Endoscopic cyclophotocoagulation (ECP) using a diode laser guided by an endoscope provides targeted ablation 
of the ciliary body under direct visualisation, while minimising surrounding tissue damage. ECP is gaining its 
popularity in the UK with currently 14 centres using the technology. The technique of combining 
phacoemulsification with endoscopic cyclophotocoagulation (phaco-ECP) has emerged as a viable option to 
simultaneously treat both cataract and glaucoma.2 The inherent advantages of the combined procedure include a 
single recovery period and effective reduction in IOP.3 
 
Cataract surgery can correct refractive error by accurate selection of appropriate intraocular lens (IOL) power.4 
As ECP causes contraction of the ciliary processes and the zonules insert on these processes, it may be 
hypothesised that this would change the effective position of the IOL which might in turn alter the post-
operative refractive outcome adversely. The aim of this study was to investigate the refractive outcome of the 
combined phaco-ECP. 
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Materials and Methods  
 
Patients 
 
The case records of 103 consecutive eyes that underwent phaco-ECP and 62 eyes of age-matched glaucoma 
patients who underwent phacoemulsification alone at a single tertiary referral center (The Western Eye Hospital, 
London, UK) between January 2006 and August 2012 were reviewed retrospectively. Patients with open angle 
glaucoma were included in the study, including normal tension, pseudoexfoliation, and pigmentary glaucoma 
subtypes. Patients with complete demographic, operative and follow-up data were subsequently entered into the 
study.  Excluded from the study were patients referred from other centres for phaco-ECP procedures and 
subsequently had follow-up appointments at their local clinics and those who had visual acuities of counting 
fingers or worse or who were lost to follow-up. Pre- and post-operative Snellen visual acuities (VA) were 
recorded. Refraction was obtained by autorefraction performed at clinic visits (Canon Auto ref-keratometer RK5) 
or subjective refraction reported by optometrists. All complications were noted. Intraocular pressure (IOP) 
measured by calibrated Goldmann applanation tonometry, mean deviation (MD) of automated Humphrey visual 
field (SITA standard 24-2) and numbers of topical or systemic anti-glaucoma agents were also recorded.  
 
Standard of Care 
 
The Royal College of Ophthalmologists’ cataract surgery guidelines 2010 set a benchmark for 85% of patients 
undergoing cataract surgery to be within +/-1.0 D of predicted refractive outcome.5 This was used as our 
standard for refractive outcome. 
 
We defined early glaucomatous damage as when the visual field MD was less than 6 decibels (dB).2 Moderate 
or advanced glaucoma cases were defined as MD of 6dB or greater. 
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Surgical details 
 
Biometry was performed with the IOL Master (Carl Zeiss Meditex, Jena, Germany); all patients were targeted to 
achieve emmetropia. The IOL power was calculated using the SRK/T formula with a standardised A constant, 
except in axial lengths less than 22mm in which case the Hoffer Q formula was used.6  
 
All procedures were performed by experienced glaucoma surgeons at the Western Eye Hospital.  The procedure 
was performed under sub-Tenon’s or peribulbar local anaesthesia. 
 
Standard cataract surgery was performed with phacoemulsification (Infinity Vision System; Alcon Laboratories, 
Fort Worth, TX, USA) using a 2.8mm temporal clear corneal incision (temporal approach was the surgeon’s 
preference), 1 to 2 side-ports and with further incisions as required to facilitate 360-degree ECP treatment. 
Foldable acrylic intra-ocular lenses were used, either HOYA PC-60AD or Rayner toric T-flex. The IOL was 
inserted in the capsular bag. Using the 20G ECP probe (E2; Endo Optiks, Little Silver, NJ, USA), 360-degrees 
photocoagulation was performed under direct visualization from the base to the tip of each ciliary process, until 
visible shrinkage and blanching occurred.   The treatment energy setting was 0.3 to 0.8 Watts (titrated under 
direct visualisation of response) with the treatment duration set to continuous. Intracameral cefuroxime 1.0mg/ 
0.1ml and subconjunctival dexamethasone 3.3mg/1ml injection (Hospira, Lake Forest, California, USA) was 
given at the end of surgery. A standard post-operative regime of 2 hourly dexamethasone and 6 hourly 
chloramphenicol drops were given over a 4-6 week period titrated according to post-operative inflammatory 
response. Patients were instructed to continue initially with their usual glaucoma agents. All patients were 
reviewed by week 1 and then according to the clinical need, typically twice more in the first 6 weeks. The 
number of glaucoma agents was reduced if IOP, visual field progress and optic disc assessment remained 
satisfactory. 
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Statistical analysis  
 
Data are presented as mean ± standard deviation (SD) and frequency (%). The comparison between the target 
refraction and the actual post-operative refraction was made using paired t-test. The comparison between the 
phaco-ECP group and the control group was made using unpaired t-test. Statistical analysis was performed 
using R software (version 3.3.1). A p-value of less than 0.05 was considered statistically significant. Normality 
of distribution was tested with Shapiro-Wilk normality test.  
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Results 
 
Sixty-two eyes (10 patients had bilateral surgery) out of the 103 eyes, which underwent phaco-ECP at a single 
tertiary referral center (The Western Eye Hospital, London, UK) between January 2006 and August 2012, were 
included in the study with 62 eyes of 62 patients who had phacoemulsification alone as the control group. The 
mean age for the phaco-ECP group and the control group was 76 (SD±12) years and 74 (SD±11) years, 
respectively. In the phaco-ECP group, 58.3% of the patients were male and in the control group 37% of the 
patients were male. The mean follow-up period for all patients was 21 months (range 2 week to 6 year 2 
months). The mean visual field MD was -17.01dB (ranging from -2.44dB to -30.2dB) for the phaco-ECP group. 
The pre-operative number of glaucoma agents was 2.7 ± 0.9 for the phaco-ECP group. Fifteen patients (27.8%) 
in the phaco-ECP group had previous glaucoma procedures including 13 patients who underwent 
trabeculectomy with or without mitomycin C (MMC), 1 Argon laser trabeculoplasty and 1 transcleral 
cyclodiode laser. The reasons for exclusions for phaco-ECP group are listed in Table 1.  
 
The majority of patients, 59 eyes (95.2%) in the phaco-ECP group and 61 eyes (98.4%) in phacoemulsification 
group, either improved or maintained their visual acuity (Table 2). More than three quarters of the eyes in the 
phaco-ECP group (75.8%, n=47) had 2 lines or more improvement in their VA. Three eyes in 2 patients (4.8%) 
experienced worsening of the visual acuity, of 3 to 4 Snellen lines, following the surgery. Of these, one patient 
who had bilateral phaco-ECP had a history of ocular cicatricial pemphigoid (OCP) with end stage refractory 
glaucoma. One patient had advanced age-related macular degeneration (AMD).  
 
In the phaco-ECP group, 90.3% (n=56) of all eyes achieved a refractive outcome within +/-1D of the target 
spherical equivalent refraction, whereas in the control group, 100% (n=62) of eyes achieved this (Figure 1). The 
difference between the groups is not statistically significant. The refractive outcome of both groups satisfies the 
standard established by the Royal College of Ophthalmology 2010 guidelines, which states that at least 85% of 
patients should achieve the refractive outcome within +/-1D of the target spherical equivalent refraction.7 
However, when considering the number of cases that achieved the refractive outcome within +/- 0.5D of the 
target spherical equivalent refraction in each group, there was a statistically significant difference. Less than 50% 
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of cases (48.4%) in the phaco-ECP group achieved the refractive outcome within +/- 0.5D of the target spherical 
equivalent refraction whereas 100% of cases achieved this in the control group (table 3).  The mean difference 
between the target and the actual post-operative refraction was -0.05D (SD ± 0.7D) in the phaco-ECP group and 
was 0.09D (SD ± 0.2D) in the control group.  In all three eyes where Rayner T-Flex toric lenses were used the 
post-operative refraction within +/-0.5D of the target refraction was achieved (range from -0.25D to 0.375D).  
 
Subgroup analysis of the 6 eyes, which were outside the targeted +/-1D refractive outcome in the phaco-ECP 
group, demonstrates the mean difference of -1.2D (SD ±1.68) between the target and the actual refraction. The 
majority of these eyes, 83.3% (n=5), displayed myopic shift with post-operative SE ranging between -1.19D and 
-2.72D. Only one eye (16.7%) had hypermetropic shift with a SE of +1.57D. Co-morbidities and potential 
causes for refractive surprise were studied (Table 4). One eye developed fibrinous uveitis and was treated with 
intensive topical steroid.  Five eyes had moderate to advanced field defect with mean MD -19.2dB (range from -
11.5dB to -29.8dB). Three eyes had previous trabeculectomy and the other 3 eyes had co-existing age-related 
macular degeneration. 
 
In 54 eyes in the phaco-ECP group, the data on IOP, number of glaucoma agents used and history of previous 
surgery were obtained. Pre-operative mean IOP was 20.4 ± 6.25 mmHg and the post-operative IOP mean was 
14.4 ± 3.95 mmHg. There was an average of 6.0 mmHg, or 29.4% reduction of IOP. Fifty-three eyes (98.1%) 
had post-operative IOP equal to or less than 21 mmHg. Seven eyes (13.0%) achieved this without any topical 
medication post-operatively. There was an average 29.6% reduction of number of glaucoma agents (from 2.7 to 
1.9).  Both the reduction in IOP and the number of glaucoma agents were statistically significant (Table 5).   
 
Complications 
 
Four eyes (6.5%) in the phaco-ECP group developed marked post-operative uveitis and required a more 
intensive post-operative topical steroid regime. All of these eyes had VA of 6/6 at their last follow-up. One eye 
(1.6%) developed fibrinous uveitis with a pupillary membrane and required YAG laser. One eye with advanced 
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glaucoma required intracameral tissue plasminogen activator injection with synechiolysis 1 month after phaco-
ECP. The BCVA of hand movement (HM) remained unchanged but this was not unexpected. One patient, with 
pre-existing OCP and bilateral juxtafoveal telangiectasia, developed post-operative macular oedema. There were 
no cases of hypotony, lens subluxation or dislocation and there was no case that required a capsular tension ring.  
No complication occurred in the phacoemulsification group.  
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Discussion 
 
In this study, we demonstrated that the refractive outcome of phaco-ECP is comparable to the control group who 
underwent phacoemulsification alone with the majority of eyes, 90.3% achieving within +/-1D of the target 
refraction using current validated formulae for biometry. This meets the Royal College of Ophthalmology 
guideline for cataract surgery.5 Also almost half of our refractive outcome for the eyes in the phaco-ECP group 
was within 0.5D of the target; this is similar to the 55% reported in previous phacoemulsification-only study.7 In 
our series, all of the eyes in the phacoemulsification only group achieved within 0.5D of the target refraction.  
 
Five of the 6 patients who were not within +/-1D of the target refraction in the phaco-ECP group experienced 
myopic shift. This may be explained by possible anterior displacement of the intraocular lens caused by zonular 
contraction following cyclophotocoagulation. The average age of the patients who did not achieve the target 
refractive outcome was older 81.5 ± 11.5 years compared to the patients who achieved the target refractive 
outcome, 76 ± 7.9 years even though the difference was not statistically significant (p=0.61). Zonules may 
become weaker due to age and this could contribute to the higher degrees of zonular movement when 
cyclophotocoagulation energy was applied to the adjoining ciliary processes, which in turn causes anterior 
displacement of the intraocular lens, thus myopic shifts.  Another possible explanation is the difference in the 
power of cyclophotocoagulation used during phaco-ECP. However as the end-point is the whitening and 
shortening of ciliary process, which is observed under visualization, it is unlikely over- or under-treatment 
occurred.  
 
Our group chose to treat 360-degrees of ciliary processes, as we believe it facilitates maximum IOP reduction. 
Other groups have also reported this as their preferred treatment protocol.8 Ciliary body rotation via external 
indentation, as advocated by some in order to optimise access to additional posterior rows of ciliary processes 
and to treat the maximum possible surface area of each ciliary process, was not performed.9 There were no cases 
of hypotony. 
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Regarding our visual acuity outcome, 4.8 % (n=3) experienced worsening of the visual acuity following phaco-
ECP. All three eyes had co-existing macular pathologies including bilateral ocular cicatricial pemphigoid and 
post -operative macular oedema in two eyes and one eye with age-related macular oedema. This could be due to 
the guarded prognosis in patients with advanced glaucoma due to impaired optic disc function and coexisting 
macular pathologies in both eyes. Also these patients who have been treated with multiple topical glaucoma 
agents are likely to have suffered from corneal epithelial toxicity, which can compromise the visual outcome. It 
has been also noted that 50% of our cohort had visual acuity of 6/9 or better pre-operatively. This may produce a 
ceiling effect hence failing to show further VA improvement following phaco-ECP. These factors may explain 
why our VA outcome may differ from a previous report by other group,2 where no patients lost BCVA as they 
only included the early glaucoma populations.  
 
Limitations of the study 
 
The main limitation of the study is that it is retrospective. A larger prospective series will be useful to determine 
whether there are any characteristics of the patients who are more likely to be refractive surprises. In addition, 
our post-operative refraction was obtained at various periods after the procedure and was obtained by 2 different 
methods (subjective and autorefraction). The change of post-operative refractive SE over time has only been 
studied on standard phacoemulsification cases. It demonstrated that there was no significant difference among 
the values at 1 week, 1 month, and 4 months.10, 11 However such data does not exist with phaco-ECP and it is 
possible that the refractive error may not have stabilised and continues to change over time when our refraction 
readings were taken. Also, other parameters maybe useful in future studies to investigate causes of visual loss 
and refractive surprise, such as pre- and post-operative macular OCT and corneal endothelial cell count. 
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Conclusions 
 
Refractive outcome after phaco-ECP is comparable to phacoemulsification alone. This study suggests that the 
refractive outcome may be more variable when the eye undergoes phaco-ECP rather than phacoemulsification 
alone. However, the majority of patients will achieve the refractive outcome within 1D of the target spherical 
equivalent. Therefore, the intraocular lens power can be selected as for phacoemulsification alone. The authors 
recommend that no modification of biometry formulae is necessary for the eyes that undergo phaco-ECP. 
Phaco-ECP should be considered as an effective, safe and predictable surgical treatment option for glaucoma 
patients with co-existing cataract.  
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Figure Captions 
 
Fig. 1 Variance of the difference between the target and the actual spherical equivalent refraction in dioptres for 
the phaco-ECP group and the phacoemulsification only control group.   
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